RxDoctor Payments Data

Alan Pollack, MD

Ophthalmology · Alexandria, VANPI 1629063052

Payments from drug & device makers

$4,336in general payments, 2019–2025

Across 179 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$777
  • Sun Pharmaceutical Industries Inc.$737
  • Tarsus Pharmaceuticals, Inc.$564
  • AbbVie$378
  • Kala Pharmaceuticals, Inc.$341
  • Johnson & Johnson Surgical Vision, Inc.$279
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,317100%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,336 in reported general payments places this provider in the 80th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$578,672
Medicare patients
1,505
Services billed
4,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine152$208,592
LumiganBimatoprost88$45,737
Cyclosporine70$39,917
MieboPerfluorohexyloctane/Pf26$19,513
Restasis MultidoseCyclosporine17$18,390
Travoprost78$18,213
Loteprednol Etabonate36$6,611
CombiganBrimonidine Tartrate/Timolol11$4,941
Latanoprost335$4,730
Timolol Maleate48$4,525
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat133$3,000
Tobramycin-DexamethasoneTobramycin/Dexamethasone58$2,397
ValacyclovirValacyclovir Hcl11$1,866
Fluorometholone14$1,213
Atropine Sulfate18$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan$378$277,660268 claims
Bausch & Lomb Americas Inc.Miebo$110$19,51326 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$56$6,61136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →